Latest updates from Novobay Biotech on precision medicine, companion diagnostics, and molecular diagnostics innovation.
China's precision oncology market has expanded at 35% CAGR over the past three years, driven by NGS panel availability, falling liquid biopsy costs, and an increasing number of targeted therapies matching genomic alterations. More than 200 Chinese hospitals now offer in-house or outsourced NGS panels.
China's national cancer screening programme — targeting lung, liver, gastric, colorectal, oesophageal, and cervical cancers — has begun incorporating liquid biopsy as a supplementary screening modality. Several provinces are now piloting blood-based multi-cancer detection tests alongside traditional imaging and endoscopy.
Comprehensive review published in a leading journal explores how novel molecular POCT technologies are essential for responding to present clinical diagnostics on infectious diseases as well as cancers, and for enabling rapid genetic testing for personalized medicine.
A comprehensive guide to China's tumor genetic testing IVD regulatory pathway covers NMPA registration requirements for NGS, PCR, and methylation diagnostics, clinical evaluation pathways, CDx co-development rules, and the LDT pilot program.
The cancer companion diagnostics market is valued at $15 billion in 2025 and projected to reach $45 billion by 2033, driven by NGS technology, personalized medicine adoption, and rising cancer prevalence worldwide. Key players include Illumina, Roche, and Thermo Fisher.
Presented at EACR26 by Prof. Daniel Kim (UC Santa Cruz), this work demonstrates how long-read sequencing of cell-free RNA from blood can expand liquid biopsy beyond detection toward biological intelligence and interpretation, unlocking novel biomarker discovery and cancer early detection.
Published in Frontiers in Oncology, this review highlights how long-read sequencing overcomes the limitations of short-read methods in detecting and resolving structural variants (SVs), haplotypes, and complex genomic rearrangements in circulating tumor DNA — capabilities critical for comprehensive cancer profiling.
The EU-funded LUMINA project tackles minimal residual disease in lung cancer — where up to 60% of patients treated with curative intent experience relapse — by integrating RNA and DNA circulating biomarkers with advanced predictive models for early relapse detection from blood and urine samples.
A review published in the Journal of Hematology & Oncology covers the latest advances in long-read sequencing for hematological malignancies presented at the 2025 ASH Annual Meeting, highlighting Oxford Nanopore Technologies and PacBio platforms for WGS, single-cell RNA-seq, and structural variant detection.
As demand for biomarker-based CDx tests in precision oncology grows, a clear understanding of regulatory frameworks — especially analytical and clinical performance requirements — is imperative to ensure safety and efficacy and aid treatment decisions for cancer patients.